All data pertaining to Covid vaccine trials should be made public: PMSF

The decision to grant Emergency Use Authorization (EUA) may be revisited once the Phase 3 trials are completed, PMSF said

A national association of doctors and scientists has demanded that all data pertaining to Covid-19 vaccine trials should be made public to enable scientists and healthcare workers to make informed choices regarding administration of vaccination.

In a statement issued on Sunday, the Progressive Medicos and Scientists Forum said the Clinical Trial (PMSF) Phase 3 data should be evaluated in a transparent manner as and when available for India for both vaccines and the decision to grant Emergency Use Authorization (EUA) may be revisited once the Phase 3 trials are completed.

They demanded that all data pertaining to the vaccine trials should be made public to enable scientists and healthcare workers to make informed choices regarding administration of vaccines for themselves and for their larger communities.

"All healthcare workers should have an option for opting out without any fear, coercion or any other adverse impact on them, including linking vaccination status to air travel restrictions," it said.

The body further demanded that the continuation or eligibility for working as healthcare should not have any precondition of Covid-19 vaccination, as is being done in a few countries.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel